<DOC>
	<DOCNO>NCT02495623</DOCNO>
	<brief_summary>A Randomized , Double-Blind , Parallel-Group , Placebo-Controlled , Multi-Dose Study Effect Two Dosage Strengths SYN-010 Compared Placebo Breath Methane Production Breath Methane-Positive Subjects Irritable Bowel Syndrome Constipation ( IBS-C )</brief_summary>
	<brief_title>A Study Effect SYN-010 Subjects With IBS-C</brief_title>
	<detailed_description>This Phase 2 , randomize , multi-center , multi-dose study . Sixty subject irritable bowel syndrome constipation age 18 65 , inclusive , enrol . The entire duration study may 43 day ( Screening post end-of-study [ EOS ] visit telephone call ) .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Subjects must IBSC positive breath CH4 test result ( &gt; 10 ppm ) Screening . Subject must meet modified Rome III criterion IBSC . Subject must average abdominal pain intensity score â‰¥ 3 ( scale 010 ) report Screening Baseline . Subject must average few 3 complete spontaneous bowel movement ( CSBMs ) per week . Subject must agree refrain make lifestyle change may affect IBSC symptoms time Screening end study . Subject take IBS treatment ( prescription overthecounter ) , proton pump inhibitor , laxative , antibiotic . Subject currently structural abnormality gastrointestinal ( GI ) tract disease condition affect GI motility , unexplained clinically significant symptom low GI bleeding , rectal bleeding , hemepositive stool , irondeficiency anemia , weight loss , systemic sign infection . Subject diagnose family history familial adenomatous polyposis , hereditary nonpolyposis colorectal cancer , form familial colorectal cancer . Subject report loose ( mushy ) watery stool ( Bristol Stool Form Scale [ BSFS ] score 6 7 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>